Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

denosumab

(deh-noh-SOO-mab)
A drug used to prevent or treat certain bone problems. Denosumab is used under the brand name Xgeva to prevent bone problems caused by multiple myeloma or by solid tumors that have spread to the bone. It is also used in certain patients to treat giant cell tumor of the bone that cannot be removed by surgery, and to treat hypercalcemia that is caused by cancer and did not get better after treatment with bisphosphonates. Denosumab is also used under the brand name Prolia to increase bone mass in certain patients with breast cancer or prostate cancer who have a high risk of breaking bones. It is also used to treat osteoporosis in certain patients who have a high risk of breaking bones. Denosumab is also being studied in the treatment of other conditions and types of cancer. It binds to a protein called RANKL, which keeps RANKL from binding to another protein called RANK on the surface of certain bone cells, including bone cancer cells. This may help keep bone from breaking down and cancer cells from growing. Denosumab may also prevent the loss of calcium from the bones. It is a type of monoclonal antibody. Also called AMG 162.
Search NCI's Dictionary of Cancer Terms